Literature DB >> 17356857

Are there predictive factors for the outcome of endoscopic treatment of grade III-V vesicoureteral reflux with dextranomer/hyaluronic acid in children?

Ugur Altug1, Murat Cakan, Sevgin Yilmaz, Fatih Yalçinkaya.   

Abstract

Dextranomer/hyaluronic acid (Dx/HA) copolymer has been used widely for the treatment of vesicoureteral reflux (VUR) in children since 2001. However, the factors that influence the outcome of injection therapy with Dx/HA have remained unclear. In this study, we retrospectively evaluated the outcomes in 101 consecutive children to determine the cure and to identify the factors that can impact treatment outcomes of Dx/HA injection. Endoscopic treatment with Dx/HA was performed in 133 ureters, in 101 patients with grade III-V VUR. Of the patients, 68 (67.3%) were girls and the mean age was 6.5 years. Before and after the treatment, the presence and grades of VUR were determined by voiding cystourethrograms. The patients' age, gender, laterality, preoperative reflux grade, ureteral duplication, morphology of ureteral orifice, renal hypoplasia and experience with surgery were assessed as predictive factors related to the success rates of Dx/HA injection therapy. The cure rates were 54.8% after the first injection, 66.9% after the second and 73.6% after the third injection. Patients with a high grade (grade IV or V), duplicated system, golf hole-shaped orifice and renal hypoplasia had significantly lower cure rates (P<0.05). Experience with the technique also correlated with the positive outcome of the procedure. New contralateral vesicoureteral reflux developed in five (7.2%) patients with unilateral VUR, and all of them resolved spontaneously during the first year of followup. No treatment-related significant complication was encountered. Although, endoscopic treatment of VUR with Dx/HA provides a high rate of success in children with medium or high grade VUR, treatment failure may be seen in some patients. However, we showed that endoscopic treatment with Dx/HA was effective in selected patients with grade V VUR, and we emphasize the need for further large-scale studies to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356857     DOI: 10.1007/s00383-007-1881-2

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   2.003


  21 in total

1.  Re: Endoscopic treatment of vesicoureteral reflux: 11 to 17 years of followup.

Authors:  Francesco Aragona
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450

2.  Subureteral dextranomer/hyaluronic acid injection as first line treatment in the management of high grade vesicoureteral reflux.

Authors:  Prem Puri; Martina Pirker; Nochiparambil Mohanan; Michal Dawrant; Laxman Dass; Eric Colhoun
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

3.  Endoscopic treatment of reflux: migration of Teflon to the lungs and brain.

Authors:  I A Aaronson; R A Rames; W B Greene; L G Walsh; U A Hasal; P D Garen
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

4.  Subureteral injection of Deflux for correction of reflux: analysis of factors predicting success.

Authors:  Michael T Lavelle; Michael J Conlin; Steven J Skoog
Journal:  Urology       Date:  2005-03       Impact factor: 2.649

5.  Vesicoureteral reflux and complete ureteral duplication. Conservative or surgical management?

Authors:  Kourosh Afshar; Frank Papanikolaou; Roja Malek; Darius Bagli; Jao L Pippi-Salle; Antoine Khoury
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

6.  Long-term followup of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux.

Authors:  G Läckgren; N Wåhlin; E Sköldenberg; A Stenberg
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

7.  Multicenter survey of endoscopic treatment of vesicoureteral reflux using polytetrafluoroethylene.

Authors:  P Puri; C Granata
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

8.  Long-term outcome of the endoscopic correction of vesico-ureteric reflux: a comparison of injected substances.

Authors:  Takahide Sugiyama; Tadashi Hanai; Kiyushi Hashimoto; Tohru Umekawa; Takashi Kurita
Journal:  BJU Int       Date:  2004-08       Impact factor: 5.588

9.  Endoscopic correction of vesico-ureteric reflux in duplex systems.

Authors:  H Miyakita; G K Ninan; P Puri
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

10.  [Role of the endoscopic treatment of vesicoureteal reflux. A 16-years' experience].

Authors:  N Capozza; P Caione
Journal:  Minerva Pediatr       Date:  2003-12       Impact factor: 1.312

View more
  2 in total

1.  Endoscopic Treatment of Vesicoureteral Reflux in Children with Dextranomer/Hyaluronic Acid-A Single Surgeon's 6-Year Experience.

Authors:  Hou-Chuan Chen; Chou-Ming Yeh; Chia-Man Chou
Journal:  Diagn Ther Endosc       Date:  2010-08-05

2.  The Value of PIC Cystography in Detecting De Novo and Residual Vesicoureteral Reflux after Dextranomer/Hyaluronic Acid Copolymer Injection.

Authors:  B W Palmer; M Hemphill; K Wettengel; B P Kropp; D Frimberger
Journal:  Int J Nephrol       Date:  2011-07-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.